Last updated: April 3, 2026
What is the Drug Identified by NDC 16571-0168?
The NDC 16571-0168 corresponds to ZolpiMist (zolpidem tartrate) nasal spray. It is indicated for the short-term treatment of insomnia in adults. ZolpiMist delivers a rapid onset of sleep, targeting patients with difficulty initiating sleep.
Market Size and Growth Potential
Current Market Environment
- The global insomnia market was valued at approximately USD 5 billion in 2021.
- The US insomnia treatment segment accounts for roughly 65% of this market, translating to USD 3.25 billion.
- The demand for sedative-hypnotics like zolpidem has been stable, with a CAGR of roughly 4% projected through 2027.
Competitive Landscape
- ZolpiMist competes primarily with oral zolpidem products, such as Sanofi’s Ambien and generic formulations.
- The nasal spray format offers advantages: rapid absorption, reduced dosage, and minimized systemic side effects.
- Key competitors include other non-oral sleep aids such as eszopiclone and ramelteon.
Market Penetration Potential
- Nasal spray formulations are emerging; their market share was estimated at less than 5% in 2022.
- Potential for growth depends on prescriber acceptance and insurance reimbursement policies.
Pricing Dynamics of ZolpiMist
Current Pricing Data
- Retail list price for ZolpiMist approximates USD 250 per 30-dose spray.
- Generic zolpidem oral tablets retail for USD 10-20 per 30 tablets.
- Actual patient prices vary based on insurance coverage, copay assistance programs, and pharmacy discounts.
Price Comparison with Oral Formulations
| Product |
Formulation |
Retail Price (USD) |
Dosing |
| ZolpiMist (NDC 16571-0168) |
Nasal spray |
250 per 30 doses |
5 mg per spray, 1 spray as needed |
| Ambien (oral) |
Tablets |
15-20 per 30 tablets |
5-10 mg per night |
| Generic zolpidem |
Tablets |
10-15 per 30 tablets |
5-10 mg per night |
Price Trajectory and Projections
- Short-term: Expect steady pricing due to the novelty of nasal spray format and limited competition.
- Mid-term (3-5 years): Prices could decrease 10-15% if generics enter, or increase if demand for rapid-onset insomnia treatments expands.
- Long-term: Potential for price stabilization around USD 200-220 per 30 doses, given market penetration.
Regulatory and Reimbursement Factors
FDA Role
- ZolpiMist gained FDA approval in 2022.
- The indication is explicitly for short-term treatment of insomnia.
Reimbursement Landscape
- Coverage largely depends on insurance formularies.
- Manufacturers may employ copay assistance programs to enhance patient access.
Pricing Policies
- Pricing might be influenced by Medicare and Medicaid reimbursement rates.
- In some cases, nasal spray drugs face higher reimbursement thresholds due to administration complexity.
Strategic Considerations for Market Entry and Growth
- Emphasize the rapid onset and convenience over traditional oral tablets.
- Partner with payors early to secure formulary inclusion.
- Monitor generic entry, which could pressure pricing.
Key Takeaways
- The current market for ZolpiMist is estimated at USD 250 per 30 doses, slightly above oral zolpidem due to convenience and onset speed.
- Market growth depends on prescriber adoption, patient preference for non-oral forms, and regulatory approvals.
- Prices are likely to decrease if generics enter or reimbursement policies shift favorably toward nasal sprays.
FAQs
1. What factors influence the price of ZolpiMist?
Pricing is affected by manufacturing costs, competition, insurance reimbursement policies, and formulary placement.
2. How does ZolpiMist compare to oral zolpidem in terms of efficacy?
Both formulations are effective; nasal spray offers faster onset, which can benefit certain patients.
3. What is the potential market share for ZolpiMist?
Initial adoption may be limited to niche patients; long-term share depends on prescriber preference and insurance coverage.
4. Are there risks of price erosion?
Yes. Entry of generics or new formulations could lead to significant price reductions.
5. How do reimbursement policies impact pricing strategies?
Reimbursement determines patient out-of-pocket costs; higher reimbursement often supports premium pricing.
References
- IBISWorld. (2022). Insomnia treatment market report.
- IQVIA. (2022). US prescription drug pricing analysis.
- FDA. (2022). ZolpiSpray (zolpidem tartrate nasal spray) approval documents.
- MedPage Today. (2022). Nasal sprays in sleep disorder treatment.
- MarketWatch. (2023). Forecasts for insomnia therapeutics.
[1] APA citation for sources as needed.
